Chr. Hansen A/S

annonce

Flere nøgletal og analyser?

Med en Bisbase Premium konto får du flere nøgletal for både virksomheder, koncerner og brancher samt adgang til eksklusive brancher indeholdende virksomheder nøje sammensat af eksperter. Og vil du lave dine egne analyser kan du også det! Det tager få minutter at få adgang - og det behøver ikke at koste dig noget!

Få adgang nu Læs mere

Rang Årets resultat

Rang i branche

1/55

"Top 10%"

Rang i Danmark

104/360.718

"Top 10%"

Direktion top 3

Morten Enggaard Rasmussen 6

CEO

Bestyrelse top 3

Rainer Chapour Lehmann 6	Bestyrelsesformand
Anders Lund 2	Næstformand
Morten Enggaard Rasmussen 6	Bestyrelsesmedlem

Legale ejere top 3

100%

Novozymes A/S

Tegningsregler

Selskabet tegnes af bestyrelsens formand eller bestyrelsens næstformand i forening med en direktør eller et andet medlem af bestyrelsen, eller af den administrerende direktør i forening med en direktør, eller af den samlede bestyrelse.

Stamoplysninger baseret på CVR

Navn	Chr. Hansen A/S
Binavne	Biopax A/S, CHL Bio Products A/S, CHL Bioindustries A/S, CHL Food Ingredients A/S, CHL International A/S, Chr. Hansen Biosystems A/S, Chr. Hansen's A/S, Chr. Hansen's Agro Systems A/S, Chr. Hansen's Bio Farming A/S, Chr. Hansen's Bio Systems A/S, Chr. Hansen's Lab. Danmark A/S, Chr. Hansen's Laboratorium Danmark A/S, G. C. Starup A/S, Gastronomisk Institut A/S, Gourmet Food Institute A/S, Gourmet Ingredients A/S, N. Kjærgaard-Jensen's Tekn. Kem. Fabrik, eftf. A/S, Richard Eilersen A/S, Chemical Works, Starter Corporation A/S, Chr. Hansen´s Laboratorium Danmark A/S Vis mere
CVR	12516479
Adresse	Bøge Alle 10-12, 2970 Hørsholm
Branche	Fremstilling af andre kemiske produkter i.a.n. [205900]
Etableret	01-09-1988 (36 år)
Første regnskabsperiode	01-09-1988 til 31-08-1989
Virksomhedsform	Aktieselskab
Antal ansatte	1.716 (årsværk:1.669)
Reklamebeskyttelse	Nej
Revisor	EY Godkendt Revisionspartnerselskab siden 25-06-2024
Regnskabsperiode	01-01 til 31-12
Selskabskapital	194.101.000 DKK 194.100.000 DKK (06-03-2000 - 26-01-2003) 183.500.000 DKK (24-04-1997 - 05-03-2000) 150.000.000 DKK (04-02-1994 - 23-04-1997) 100.000.000 DKK (20-07-1992 - 03-02-1994) 80.000.000 DKK (02-03-1989 - 19-07-1992) Vis mere
Vedtægter seneste	12-06-2023

Medlem af brancherne

Fremstilling af andre kemiske produkter i.a.n. [205900]
NACE6 indeholdende 77 virk.
Fremstilling af andre kemiske produkter [205]
NACE3 indeholdende 77 virk.
Fremstilling af kemiske produkter [20]
NACE2 indeholdende 481 virk.
Fremstillingsaktiviteter [C]
NACE1 indeholdende 26.313 virk.

Formål

Selskabets formål er at drive investeringsvirksomhed samt direkte eller indirekte at drive fabrikation af og handel med bioteknologiske og kemiske produkter, processer og anlæg, samt at drive forsknings- og rådgivningsvirksomhed og anden virksomhed, der efter bestyrelsens skøn er forbundet dermed. Selskabet søger i enhver henseende at drive sin virksomhed på social, miljømæssig og økonomisk ansvarlig vis.

Regnskab

	2024	2023	2022
Valuta/enhed	000' DKK	000' DKK	000' DKK
Omsætning	6.716.636 -	8.300.634 -	5.902.769 +9%
Bruttofortjeneste	3.789.689 -	4.924.126 -	3.628.690 +11%
Årets resultat	1.891.419 -	500.418 -	1.210.766 +49%
Egenkapital	10.121.940 -	6.853.651 -	7.350.185 +3%
Balance	15.728.647 -	12.617.279 -	11.715.335 +0%

Ledelsesberetning sammendrag

Ledelsesberetning

Financial Review

At December 31, 2024, Chr. Hansen A/S was fully owned by Novozymes A/S. At December 31, 2023, Chr. Hansen A/S was fully owned by Chr. Hansen Holding A/S.

Following receiving all necessary approvals and final registration of the statutory merger with the Danish Business Authority on January 29, 2024, the merger between Novozymes A/S and Chr. Hansen Holding A/S was successfully completed. Consequently Chr. Hansen A/S is now fully owned by Novozymes A/S.

The financial statements for the financial year 2024 cover the period from January 1 – December 31, 2024 (12 months). The comparative figures cover the financial period September 1, 2022 – December 31, 2023 (16 months) as the financial year was changed from September 1 – August 31, to January 1 – December 31.

Beskrivelse af virksomhedens væsentligste aktiviteter

Principal activities

Chr. Hansen A/S is a global differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical, and agricultural industries.

Chr. Hansen A/S is organized into two divisions. The divisions are Food & Health Biosolutions and Planetary Health Biosolutions.

Food & Health Biosolutions

Novonesis Group, of which Chr. Hansen A/S is a part, is the market leader in the cultures and enzymes market. Our biosolutions enable food and beverages with better taste and texture, less sugar and more fiber. They can deliver life-long health benefits with supplements that target specific health needs, including mental wellness, oral and gut health, immune as well as women’s and infant health benefits.

Our biosolutions in Food & Beverages help our customers get more from less and make processes more efficient. They enhance the nutritional value of food, while enabling better taste, texture and appearance with simpler, shorter labels, helping to meet evolving consumer demands. Our customers can also lower the environmental footprint of foods by improving productivity and reducing food waste.

Our scientifically researched and tested biosolutions in Human Health enable customers to develop supplements that serve consumers from the beginning of life to old age. They deliver a range of health benefits, including mental wellness, gut, oral, immune and women’s health benefits, enabling consumers globally to live healthier lives.

Planetary Health Biosolutions

Planetary Health Biosolutions include products for the animal and feed industry. Our biosolutions help farmers increase crop yields, while offering increased resilience to the impacts of climate change. In livestock production, our biosolutions enable animals to get more nutrients from feed and promote animal health by reducing the need for antibiotics.

Development in activities and financial position

Due to the change of the financial reporting period, the financial year 2024 comprises 12 months and the comparison period comprises 16 months (2022/23).

Chr. Hansen A/S reported net sales in 2024 of DKK 6,717 million, equal to an increase of 8% (based on a 12-months period for 2022/23 assuming even monthly net sales for the 16 months of the financial year).

Other operating income increased significantly due to a research and development cost contribution agreement between Novozymes A/S and Chr. Hansen A/S as well as the divestment of the lactase enzyme business. Please refer to the Annual Report for 2024 for Novonesis (Novozymes A/S, cvr. 10 00 71 27) to obtain further information on the divestment of the lactase enzyme business.

Operating profit (EBIT) increased to DKK 2,412 million (DKK 1,694 million in 2022/23), mainly due to the net income from the research and development cost contribution agreement with Novozymes A/S and gain from the divestment of the lactase enzyme business. The EBIT margin for 2024 was 36% compared to 20% in the previous financial year.

Financial costs were impacted by the impairment of receivables from joint ventures of DKK 97 million (DKK 527 million in 2022/23). 2022/23 was further impacted by the impairment of financial assets relating to the investment in joint ventures of DKK 244 million.

Profit before tax amounted to DKK 2,297 million compared to DKK 793 million in the previous financial year. Profit for the financial year amounted to DKK 1,891 million for 2024, compared to DKK 500 million in 2022/23.

In 2024, Chr. Hansen A/S acquired patents, trademarks and intellectual property to Human milk oligosaccharide (HMO) in the amount of DKK 1,297 million, from Chr. Hansen HMO GmbH, Germany (an indirectly owned subsidiary of Halley GmbH, Germany).

Total assets amounted to DKK 15,729 million at December 31, 2024 compared to DKK 14,294 million at December 31, 2023.

Total equity amounted to DKK 10,122 million at December 31, 2024 equivalent to an equity ratio of 64%. This compared to total equity of DKK 8,531 million and an equity ratio of 60% at December 31, 2023. Dividend of DKK 300 million was approved at the Annual General Meeting held June 25, 2024 and was subsequently paid to the sole shareholder Novozymes A/S.

In the financial year 2024, a material misstatement in a prior year relating to a contribution from the parent company of Chr. Hansen A/S to a subsidiary was identified and adjusted. The transfer of funds took place before the merger between Chr. Hansen Holding A/S and Novozymes A/S in January 2024. The adjustment amounts to DKK 1.7 billion impacting the financial statements line items “’Investments in subsidiaries’ and ’Free reserves’ within equity. The adjustment has no impact on the income statement for 2024, the 2023 comparative year or prior years.

The average number of employees was 1,614 at December 31, 2024 compared to 1,576 at December 31, 2023.

The results for the financial year 2024 exceed the results for 2023 primarily as a result of other operating income as set out above.

Uncertainty regarding recognition and measurement

No uncertainty regarding recognition and measurement has been identified by Management.

Beskrivelse af virksomhedens forventede udvikling

Outlook for 2025

Net sales are expected to increase 6-8%. Profit for the year is expected to be at the same level compared to 2024.

Intellectual capital (Creative and committed employees)

As a knowledge-based company Chr. Hansen A/S is highly dependent on having committed and motivated employees, as well as skilled managers. Chr. Hansen A/S therefore invests in the development of competences through ambitious development programs for employees and managers.

Generalforsamlingsdato: 19-06-2025